Ligand Pharmaceuticals | LGND - Operating Expenses


Ligand Pharmaceuticals reported $34.35M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Agenus USD -221.22M 241.03M Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
Anika Therapeutics USD 133.9M 103.93M Mar/2026
Arrowhead Research USD 215M 8.23M Mar/2026
Baxter International USD 6.04B 2.85B Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Eli Lilly USD 10.02B 285M Mar/2026
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Enviri Corporation USD 233.18M 357.11M Mar/2026
Gilead Sciences USD 23.52B 18.55B Mar/2026
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Glaxosmithkline GBP 9.17B 1.4B Dec/2025
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Insmed USD 506.24M 7.31M Mar/2026
Intrexon USD 61.56M 26.1M Jun/2024
Ionis Pharmaceuticals USD 364M 54M Mar/2026
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
Ligand Pharmaceuticals USD 34.35M 5.27M Mar/2026
MacroGenics USD 21.2M 32.13M Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Pacira USD 172.75M 20.93M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Veracyte USD 119.99M 3.99M Mar/2026